{"entity":{"id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","aka":[],"tldr":"A phase 1/2 trial of talazoparib and selinexor in triple-negative breast cancer, run by National University Hospital, Singapore, now recruiting.","summary":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) is a phase 1/2, interventional study registered as NCT05035745 by National University Hospital, Singapore, with a registry enrolment figure of 63 participants, started 2021-03-01 and due to reach its primary completion in 2027-11. Interventions recorded: Talazoparib; Selinexor. Conditions listed: Advanced Refractory Solid Tumors; Advanced Triple Negative Breast Cancers; Metastatic Triple Negative Breast Cancers. Triple-negative eligibility wording from the registry: \"b) Dose expansion phase: Patients with previously treated, advanced or metastatic histologically or cytologically confirmed triple negative breast cancers\". Sites: Singapore. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05035745","url":"https://clinicaltrials.gov/study/NCT05035745"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["talazoparib","selinexor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05035745","phase":"1/2","setting":"Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)","sponsor":"National University Hospital, Singapore","enrolled":63,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05035745/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}